Meta-Analysis of Botulinum Toxin Treatment of Spasmodic Dysphonia: A Review of 22 Studies

Whurr, Renata; Nye, Chad; Lorch, Marjorie Perlman

doi:10.3109/13682829809179445

Cited by 48 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[4] Botulinum toxin injections generally improve the voice for a period of three to four months, after which the voice symptoms gradually return. [1,5,6,7] Behavioral therapy and voice therapy are another form of treatment that may work in mild cases or can be used with pharmacotherapy as adjunct for increasing the duration of effect.…”

Section: Spasmodic Dysphonia Is Classified Into Three Types A) Adductmentioning

confidence: 99%

A Study of Voice Changes in Spasmodic Dysphonia After Botulinum Therapy

Singh¹,

Yadav²,

Mokamati³

et al. 2016

jemds

View full text Add to dashboard Cite

show abstract

Section: Spasmodic Dysphonia Is Classified Into Three Types A) Adductmentioning

confidence: 99%

A Study of Voice Changes in Spasmodic Dysphonia After Botulinum Therapy

Singh¹,

Yadav²,

Mokamati³

et al. 2016

jemds

View full text Add to dashboard Cite

show abstract

“…For the patient and for the physician, BT therapy of spasmodic dysphonia represents a highly satisfying indication [ 66 ]. Practically all patients benefi t from BT therapy and the degree of improvement is astonishing.…”

Section: Pharyngolaryngeal Dystoniamentioning

confidence: 99%

Botulinum Toxin Therapy of Dystonia

Dressler¹,

Kaňovský²

2015

Dystonia and Dystonic Syndromes

View full text Add to dashboard Cite

“…For spasmodic dysphonia (SD), there is data from several clinical studies and meta-analyses [Wong et al 1995;Brin et al 1998;Whurr et al 1998;Finnegan et al 1999;Boutsen et al 1998;Watts et al 2006Watts et al , 2008Blitzer, 2010]. One double-blind, placebo-controlled study examined the effects of BoNT-A versus saline in 13 adductor SD patients and revealed significant effects of BoNT-A on voice quality, perceived voice improvement and acoustic measurements [Troung et al 1991].…”

Section: Spasmodic Dysphoniamentioning

confidence: 99%

Current and future medical treatment in primary dystonia

Delnooz

Warrenburg

2012

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Dystonia is a hyperkinetic movement disorder, characterized by involuntary and sustained contractions of opposing muscles causing twisting movements and abnormal postures. It is often a disabling disorder that has a significant impact on physical and psychosocial wellbeing. The medical therapeutic armamentarium used in practice is quite extensive, but for many of these interventions formal proof of efficacy is lacking. Exceptions are the use of botulinum toxin in patients with cervical dystonia, some forms of cranial dystonia (in particular, blepharospasm) and writer's cramp; deep brain stimulation of the pallidum in generalized and segmental dystonia; and high-dose trihexyphenidyl in young patients with segmental and generalized dystonia. In order to move this field forward, we not only need better trials that examine the effect of current treatment interventions, but also a further understanding of the pathophysiology of dystonia as a first step to design and test new therapies that are targeted at the underlying biologic and neurophysiologic mechanisms. http://tan.sagepub.com dystonia are given intramuscularly, often under electromyography (EMG) guidance, and need to be repeated every 3-6 months. Contraindications for the use of BoNT include history of neuromuscular disease, e.g. myasthenia gravis, LambertEaton syndrome or motor neuron disease, and a history of hypersensitivity to BoNT, albumin or saline. BoNT injections are also contraindicated in combination with aminoglycoside, penicillamine, quinine and calcium-channel blockers as the effect of these drugs may be potentiated. As teratogenicity of BoNT is still unknown, it is advised not to use BoNT during pregnancy and lactation. Keywords Cervical dystoniaBoNT injections are the first-line therapy for cervical dystonia (CD). Meta-analysis of several double-blind, placebo-controlled trials have demonstrated a beneficial effect of the BoNT type A (BoNT-A) versus placebo on multiple domains, such as dystonia severity, pain and the patient's and physician's subjective judgement. Adverse events are usually transient and mild. The most relevant side effects, of increasing frequency with higher doses and therefore dose-limiting, are neck weakness, dysphagia, dry mouth/sore throat and voice changes/hoarseness. Others are doseindependent and include pain at the site of injection, malaise, upper respiratory infection and headache [Costa et al. 2005b].BoNT also has proven long-term safety and efficacy. Several large case series have shown treatment efficacy up to 10 years, without longterm adverse effects [Blackie and Lees, 1990;Haussermann et al. 2004]. The occurrence of a secondary nonresponse, likely due to antibodies to BoNT or other components, was rare (1-2%) [Kessler et al. 1999;Haussermann et al. 2004;Brin et al. 2008]. Also primary nonresponse is seen, but reports documenting its occurrence are sparse [Truong et al. 2005]. A comparison of efficacy and safety between two preparations of BoNT-A, (onabotulinumtoxinA [Botox ® ] and rimabotulinumtoxin...

show abstract

Meta-Analysis of Botulinum Toxin Treatment of Spasmodic Dysphonia: A Review of 22 Studies

Cited by 48 publications

References 0 publications

A Study of Voice Changes in Spasmodic Dysphonia After Botulinum Therapy

A Study of Voice Changes in Spasmodic Dysphonia After Botulinum Therapy

Botulinum Toxin Therapy of Dystonia

Current and future medical treatment in primary dystonia

Contact Info

Product

Resources

About